Analysis of intratumoral immune response early on Nivolumab treatment in unresectable advanced or recurrent gastric cancer. - Intratumoral immune response early on Nivolumab treatment in gastric cancer.

The University of Tokyo0 个研究点目标入组 19 人开始时间: 2017年10月19日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Synchronous or metachronous (within 5 years) double cancers, except for intoramucosal tumor curatively resected by local therapy 2.Active infection requiring systemic therapy. 3.Active autoimmune diseases or with a history of chronic or repetitive autoimmune diseases. 4.With a history of interstitial pneumonia, pulmonary fibrosis or irradiation pneumonitis. 5.Active diverticulitis or inflammatory bowel disease. 6.Poorly controlled diabetes mellitus or thyroid diseases. 7.Unstable angina within 3 weeks or with a history of acute myocardial infarction within 3months. 8.Severe psychological illness. 9.Pregnant or lactating women or women of childbearing potential. 10.Within 4 weeks after live vaccination or 2 weeks after inactiviated vaccination. 11.Judged to be unfit to participate in this study by investigater.

发起方